Phase 3 N=498 Simplifying the Rabies Pre-exposure Vaccination
Rabies
Primary: Number of Participants With a Boostability of the Rabies Antibodies After Booster Vaccination — 185; 183 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=33 Immune Response After Booster Vaccination in HIV - Infected Patients Who Received Rabies Primary Vaccination
HIV · Rabies
Primary: Rabies Neutralizing Antibody Titers — 8.48 IU/ml
Phase 2 N=164 A Comparison of the Safety, PD and PK of a Single Dose of SYN023 Administered With Licensed Rabies Vaccines
Human Rabies
Primary: Percentage of Participants With Serum Rabies Virus Neutralizing Activity — 94.3; 97.1; 97.1; 100 percentage of participants — p=0.4187
Phase 4 N=37 Responses to Rabies Vaccine in Adults With or Without Antibiotics
Rabies Human
Primary: Antibody Titers — 217.39; 805.64 IU/mL
Phase 3 N=1,000 A Phase III Clinical Study to Evaluate SYN023's Efficacy and Safety
Rabies · Communicable Disease · Virus Diseases
Primary: Rabies Virus Neutralizing Activity (RVNA) of Geometric Mean Concentration (GMC) at Study Day 8 — 4.346; 0.232 IU/mL
Phase 2 N=448 Comparison of SYN023 to Human Rabies Immune Globulin in Post Exposure Prophylaxis of Rabies
Rabies
Primary: Rabies Virus Neutralizing Activity (RVNA) of Geometric Mean Concentration (GMC) at Study Day 8 — 4.70; 0.13; 3.30; 0.17 IU/mL
Phase 3 N=162 Safety and Effectiveness of BPL HRIG With Active Rabies Vaccine in Healthy Subjects
Healthy
Primary: Proportion of Subjects With Anti-rabies Antibody Titer of ≥0.5 IU/mL — 73; 72 Participants — p=0.0006
Phase 2 N=320 Immunogenicity and Safety of a Purified Vero Rabies Vaccine
Rabies Virus
Primary: Rabies Virus Neutralizing Antibody (RVNA) Geometric Mean Titers (GMTs) Against Rabies Virus at Day 0 — 0.101; 0.100; 0.102; 0.101 international units per milliliter
N/A N=105 Immune Response in Adults to PrEP and Simulated Booster PEP With a New CPRV
Efficacy of the New CPRV
Primary: Rabies Neutralizing Antibodies Determine by Rapid Fluorescent Focus Inhibition Test (RFFIT) — 0; 0; 0 International unit per ml
Phase 4 N=59 Immunogenicity of Rabies Vaccine for Pre Exposure Prophylaxis
Rabies
Primary: Protective Humoral Immune Response at 1 Month Post First Vaccination. — 12; 12; 12; 11 Participants
Phase 3 N=640 Study of Purified Vero Rabies Vaccine Compared With Two Reference Rabies Vaccines in a Simulated Post-Exposure Regimen in Adults
Rabies (Healthy Volunteers)
Primary: Percentage of Participants With Rabies Virus Neutralizing Antibody (RVNA) Titers Greater Than or Equal to (>=) 0.5 International Units Per Milliliter…
Phase 1 N=50 Dosage-Escalation Study of the Safety and Immunogenicity of a Novel Rabies Vaccine ChAd155-RG vs. the Comparator RABAVERT Vaccine in Healthy Adult Subjects
Rabies · Rabies Immunisation
Primary: Number and Percentage of Participants With Solicited Injection Site Reactogenicity Events in Each Treatment Arm and Overall — 3; 2; 0; 0 Participants
Phase 4 N=103 Effect of Antimalarial Drugs to Rabies Vaccine for Post-exposure Prophylaxis.
Rabies
Primary: Geometric Mean Titer (GMT) 14 Days Post Fourth Dose Post Exposure Prophylaxis (PEP) With Purified Chick Embryo Cell Vaccine (PCECV) in Each Malaria Prophylaxis Group…
Phase 3 N=118 Phase II/III Study of the Safety and Effectiveness of HRIG With Active Rabies Vaccine in Healthy Subjects
Rabies
Primary: The Difference Between KamRAB and HRIG Comparator, in the Proportions of Subjects With Serum Anti-rabies IgG Antibody Concentration ≥ 0.5 IU/mL — 55; 58 Participants
Phase 3 N=459 A Phase 3 Clinical Trial to Evaluate Long-term Immunogenicity and Boostability of Purified Chick-Embryo Cell Rabies Vaccine in Adults Following Primary Series of Pre/Exposure Prophylaxis.
Virus Diseases · Rabies
Primary: Number of Participants Reporting Serious Adverse Events (SAEs) After a Booster Dose of Purified Chick Embryo Cell Culture (PCEC) Rabies Vaccine — 2; 0; 3 Participants
Phase 4 N=250 Immunogenicity and Safety of Rabies Vaccine, Administered With Two Different Simulated Post Exposure Schedules
Rabies
Primary: Geometric Mean Rabies Virus Neutralizing Antibody (RVNA) Concentration in Each of the Zagreb and Essen Groups on Study Day 14 — 0.09; 0.099; 12; 12 IU/mL
Phase 3 N=885 Safety and Immunogenicity of Two Intradermal Rabies Vaccine Regimens Administered With and Without Human Rabies Immunoglobulin in Subjects ≥ 1 Years of Age
Rabies Infection
Primary: Percentages of Subjects With RVNA Titer >= 0.5 and Vaccine Group Differences ("4-sites, 1-week" to That of "2-sites, TRC" ID PEP Regimen of the PCEC Rabies Vaccine With…
Phase 1 N=60 FMP2.1/AS02A: Rabies Vaccine Malaria-Experienced Adults in Bandiagara, Mali
Malaria · Plasmodium Falciparum Malaria
Primary: Safety and Reactogenicity (SAEs and AEs) — 45; 53; 22; 37 Number of events
Phase 3 N=1,708 Study of Purified Vero Rabies Vaccine Compared With Two Reference Rabies Vaccines, Given in a Pre-exposure Regimen to Children and Adults and as Single Booster Dose to a Subset of Adults
Rabies · Healthy Volunteers
Primary: Primary Series Cohort 1: Percentage of Participants With Rabies Virus Neutralizing Antibody (RVNA) Titer Greater Than or Equal to (>=) 0.5 IU/mL — 100; 100; 100; 100…
Phase 3 N=661 Safety and Immunogenicity of 2 Different Vaccination Schedules of Rabies and Japanese Encephalitis Vaccines in Healthy Adult Subjects
Rabies · Japanese Encephalitis
Primary: Percentages of Subjects With RVNA Concentrations ≥0.5 IU/mL At 7 Days After Last Active Vaccination — 100; 100 Percentages of subjects
Phase 1 N=53 A Study to Assess the Safety, Reactogenicity and Immune Response of CureVac's Candidate Rabies mRNA Vaccine in Healthy Adults
Rabies
Primary: Number of Participants Who Experienced a Local Solicited Adverse Event (AE) Post Dose 1 (Day 1) — 13; 15; 10; 5 Participants
Phase 3 N=644 A Randomized, Open-label Study Comparing Two Different Rabies Vaccine Schedules in Chinese Children and Older Adults
Rabies
Primary: Non-inferiority in Immune Response of the Zagreb Postexposure Schedule of Rabipur to That of the Conventional Essen Postexposure Schedule of Rabipur as Measured by GMC…